September 20, 2017
CHICAGO – The Recurrence Score, a tool used to predict risk of relapse in renal cell carcinoma, appears effective in high-risk disease, according to an analysis of the S-TRAC trial presented at the ASCO Annual Meeting.
“Adjuvant therapy with sunitinib compared with placebo prolonged DFS in 615 patients with high-risk renal cell carcinoma (HR, 0.76; P = .03) in the S-TRAC trial,” the researchers wrote. “The 16-gene Recurrence Score was developed and validated to predict risk of recurrence of renal cell carcinoma after nephrectomy in 2 cohorts of stage 1-3 patients. We present further validation of Recurrence Score results.”